BridgeMD
A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
EU CTIS ID: 2022-502031-20-00
What this study is testing
To evaluate the efficacy of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) on the basis of confirmed objective response rate (ORR) and progression-free survival (PFS), as assessed by investigators according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) (Phase 2) and to evaluate the efficacy of Arm A compared with Arm B on the basis of PFS, as determined by the investigator according to RECIST v1.1, and overall survival (OS) (Phase 3)
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- 2. Histologically or cytologically documented locally advanced unresectable or metastatic non-squamous NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
- 3. No prior systemic treatment for metastatic non-squamous NSCLC
- 4. Known tumor PD-L1 status
- 5. Measurable disease, as defined by RECIST v1.1
- 6.Negative HIV test and Serology test negative for active hepatitis B virus and active hepatitis C virus at screening
You likely can't join if
- 1. Patients with NSCLC which harbors a mutation in the EGFR gene or an ALK fusion oncogene
- 2. Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- 3. Active or history of autoimmune disease or immune deficiency
- 4. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
- 5. History of malignancy other than NSCLC within 5 years prior to randomization, with the exception of malignancies with a negligible risk of metastasis or death
- 6. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte-associated protein 4 (CTLA4), anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- United Kingdom
- Japan
- Switzerland
- China
- Korea, Republic of
- New Zealand
- Canada
- Turkey
- United States
- Taiwan
- Hong Kong
- Thailand
- Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; United Kingdom; Japan; Switzerland; China; Korea, Republic of and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.